Sight Sciences (SGHT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SGHT Sight Sciences

Watchlist

3.570
+0.210+6.25%

Close Dec 20 16:00 ET

3.570
0.0000.00%

Post 16:20 ET

181.19MMarket Cap-3.53P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Lake Street Maintains Sight Sciences(SGHT.US) With Hold Rating, Maintains Target Price $5
Moomoo NewsDec 20 14:31 ET · Ratings
Lake Street Issues a Hold Rating on Sight Sciences (SGHT)
TipRanksDec 20 13:39 ET · Ratings
Sight Sciences Does BIA of TearCare to Treat MGD-associated DED in US
TipRanksDec 19 16:21 ET
Sight Sciences Announces the Results of a Budget Impact Analysis for Its TearCare System for the Treatment of Meibomian Gland Disease ("MGD") Showing Cost Savings Over Existing Reimbursed Treatment Options
GlobeNewswireDec 19 16:05 ET
Sight Sciences Is Maintained at Neutral by Citigroup
Dow JonesDec 11 14:32 ET · Ratings
Citi Maintains Sight Sciences(SGHT.US) With Hold Rating, Cuts Target Price to $4.6
Moomoo NewsDec 11 07:31 ET · Ratings

Comments

Jaguar8

Oct 14 15:06

NEWS

$Sight Sciences (SGHT.US)$
Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial
Sight Sciences (Nasdaq: SGHT) announced the publication of a new study in Clinical Ophthalmology, demonstrating the efficacy of TearCaretreatment for dry eye disease (DED). The study, titled 'Impact of TearCare on Reading Speed in Patients with Dry Eye Disease,' revealed significant improvements in various metr...

Jaguar8

May 28 15:06

NEWS

$Sight Sciences (SGHT.US)$
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Sight Sciences announced the publication of twelve-month results from the SAHARA trial, showing clinically meaningful improvements in dry eye disease for patients who switched from Restasis to the TearCare treatment. Phase 2 of the trial included 163 patients who had used Rest...

Jaguar8

Apr 10 15:32

$Sight Sciences (SGHT.US)$
NEWS
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Sight Sciences, Inc. (Nasdaq: SGHT) announces results of a large-scale MIGS study comparing three leading technologies in glaucoma patients. OMNI technology shows significant IOP and...

Stock Region

Apr 3 10:09

Ophthalmology Company Reports Promising Dry Eye Disease Treatment Results

Revolutionizing Glaucoma and Dry Eye Treatment: Insights from Sight Sciences' Groundbreaking Clinical Trials.
In the realm of ophthalmology, groundbreaking advancements are not just welcomed; they are necessary. As we navigate through the complexities of eye diseases, companies like Sight Sciences are leading the charge with innovative solutions that promise not only relief but also a renewed hope for millions globally. Rec...

Moomoo AI

Dec 27, 2023 05:38

Sight Sciences' high P/S ratio may be precarious given forecasted revenue declines, posing the risk of a future drop in share prices despite recent gains.